Dimerix holds pre-IND meeting on DMX-200 with FDA
25 November 2019 MELBOURNE, Australia: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company, today confirmed that the US Food and Drug Administration (FDA) met with Dimerix for a Pre-Investigational New Drug (pre-IND) meeting. At the pre-IND meeting, the…
Seed Health and Atmo Biosciences announce research partnership to evaluate impact of probiotics on gut microbiome
25 November 2019 Seed Health, a US-based microbial sciences company, and Atmo Biosciences, a digital health business incubated by healthtech commercialization company Planet Innovation, have announced a research partnership to use Atmo’s ingestible gas-sensing capsule to study the…
Hemideina raises $4 million in series A round signalling strong market support
16 November 2019 MELBOURNE, AUSTRALIA: Hemideina, a hearing solutions company focussed on the development and commercialisation of the Hera Wireless Implant, announced today that it successfully raised a Series A investment of $4 million in their second round…
La Trobe University Launch Medicinal Agriculture Hub
15 November 2019 Education Minister Dan Tehan today launched a major medicinal agriculture research hub at La Trobe University where work is underway to optimise the production of active components in medicinal plants, particularly medicinal cannabis, and to identify their…
Sienna and VivaZome to Evaluate EXO-NETTM for VivaZome’s Exosome-based Therapeutics
8 November 2019 Melbourne, Australia: Sienna Cancer Diagnostics Ltd (ASX: SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative In-Vitro Diagnostic (IVD) tests, has entered into an agreement with Melbourne-based VivaZome Therapeutics Pty Ltd…
Immutep presents positive interim data from Phase II TACTI-002 Trial at SITC
8 November 2019 SYDNEY, AUSTRALIA – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, reports positive interim data from its open label TACTI-002 Phase…
PI to manufacture Scinogy’s new cell processing system for cell therapy manufacture
8 November 2019 Planet Innovation is partnering with Melbourne-based start-up Scinogy to manufacture a revolutionary new cell processing system that is being commercialized by global biotechnology company Thermo Fisher Scientific. The Gibco™ CTS™ Rotea™ Counterflow Centrifugation System has the potential…
Weaning ourselves off opioids – Monash researchers use nanotechnology for pain relief
7 November 2019 Researchers at the Monash Institute of Pharmaceutical Sciences (MIPS) and the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology (CBNS) have created a nanoparticle that could improve the properties of painkillers by delivering…
Leading Australian health accelerator announces key commercial outcomes at global HLTH conference
30 October 2019 ANDHealth, Australia’s leading health technology accelerator which focuses solely on supporting the commercialisation of disruptive and digital health technologies, today announced the two year commercial growth outcomes of its first 10 ANDHealth+ cohort companies. Since…
Marketing email using BioMelbourne Network name – please ignore
1 November 2019 Some BioMelbourne Network members have received an email like this one using the BioMelbourne Network name. If you receive this or something similar, please ignore it. This has nothing to do with BioMelbourne Network and…
4Dx Celebrates Confirmatory Clinical Trial Success of its XV Lung Imaging Technology
29 October 2019 Melbourne, Australia, 29 October 2019 Australian medical technology company 4Dx Limited has attained excellent results in a major clinical trial of its patented four-dimensional lung imaging technology. The confirmatory clinical trial showed that XV Technology™…
David Haylock, PhD Appointed as Chief Executive Officer
30 October 2019 Melbourne, Australia: VivaZome Therapeutics Pty Ltd (“VivaZome”) is pleased to announce that Dr David Haylock has been appointed as Chief Executive Officer (CEO), effective as of 01 November, 2019. Dr Haylock has collaborated with VivaZome…
